InvestorsHub Logo
Followers 32
Posts 1683
Boards Moderated 0
Alias Born 01/11/2014

Re: None

Friday, 05/10/2019 1:32:56 AM

Friday, May 10, 2019 1:32:56 AM

Post# of 3516
From ph2GBM trial ' The tumors in 27 (73%) of these 37 tumor-bearing patients regressed during this trial. The addition of TSC to the SOC resulted in tumor reductions greater than 40% in 21 of the 37 patients. Perhaps the most significant result is the complete disappearance (100% reduction) of tumor in 11 patients (30%)'. How is it possible that no BP has provided its support to advance such a brilliant drug. 57% ORR (of which 30% CR!) is unheard of in GBM. They must be waiting for the initial ph3 8 people results to get better terms , I guess.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DFFN News